Delhi, August 29, 2023 - Tuberculosis (TB) remains a pressing public health concern in India, where the country shoulders a significant portion of the global TB burden. In a dedicated effort to combat the disease and improve treatment outcomes, HEAL Foundation, supported by Mylan Pharmaceuticals Private Limited (a Viatris company), has proudly launched the India Fights TB initiative. The new program aims to spread awareness and enhance treatment adherence among TB patients in India.
India currently bears the highest burden of TB cases worldwide, with approximately 2.64 million cases reported in 2022 alone. Despite notable advancements in TB treatment and control, challenges such as low awareness, persistent stigma, and treatment non-adherence continue to hinder progress. Recognizing the urgent need to address these issues, HEAL Foundation has taken a proactive step forward with launch of India Fights TB initiative.
R Shankar, President, HEAL Foundation, expressed his unwavering commitment to tackling the TB crisis in India. He stated, "TB remains a significant public health challenge in our country. Through the India Fights TB initiative, we aim to create widespread awareness about the disease, its symptoms, and the critical importance of early diagnosis and treatment adherence. By educating the public and fostering a supportive environment, we can work towards reducing the stigma associated with TB and empower patients to complete their treatment."
Ajay Bhatia, Head of Commercial Operations India, Viatris, said, “Partnerships and collaborations are critical, as are policies and strong healthcare systems that allow for healthy competitive environments. At Viatris, we work with organizations across the globe in the public and private domain to support sustainable access to high quality medicines. We are proud to support the India Fights TB initiative launched by HEAL Foundation. Tuberculosis remains a formidable health concern in India, which requires a collective effort from all stakeholders to combat the disease effectively. Through the initiative, we aim to spread awareness about TB, help enhance treatment adherence, and enable better treatment outcomes for patients in India. Our commitment to addressing the TB crisis in India is resolute, and we believe that by working together, we can make a meaningful difference in the lives of those affected by the disease.”
Dr Dhara Shah, Head of Medical Affairs, Viatris India, said, “TB eradication in India is at a crucial juncture. The government is spearheading the TB elimination program to end TB by 2025. Via the India Fights TB initiative, we will provide accurate information to patients, caregivers, and the community at large regarding TB diagnosis and treatment through an effective communication strategy to support health seeking behaviour. We hope this will help empower patients and their family members to rise above the stigma of TB related to the disease and support their journey to access information, treatments and better outcomes. Access is fundamental to our mission of empowering people worldwide to live healthier at every stage of life.”
India Fights TB encompasses a comprehensive range of strategies to address the multifaceted challenges of TB control. The initiative's official website, www.indiafightstb.com, will serve as a centralized platform offering a wealth of information about TB, its prevention, and treatment. Visitors can access educational materials, informative videos, and frequently asked questions to enhance their understanding of TB and its management.
The launch of India Fights TB marks a significant stride in HEAL Foundation's ongoing commitment to addressing critical healthcare challenges in India. By spreading awareness, combating stigma, and promoting treatment adherence, this initiative has the potential to make a tangible impact on the lives of TB patients and contribute to the overall goal of eliminating TB from the country, added Shankar.
For more information about India Fights TB and to access valuable resources, please visit the official website at www.indiafightstb.com.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter, LinkedIn, Instagram and YouTube.
